Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
Browse
News
Browse
Subscribe

Conference News

EHA 2019: Acalabrutinib shows remarkable benefit in relapsed or refractory chronic lymphocytic leukaemia

(15 Jun 2019)

EHA 2019: Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related death in relapsed / refractory multiple myleoma

(15 Jun 2019)

EHA 2019: Burning out the T-ALL engine: NADK is a new therapeutic target in T-cell Acute Lymphoblastic Leukaemia

(15 Jun 2019)

EHA 2019: Overcoming the "Don’t Eat Me" signal of refractory lymphomas

(15 Jun 2019)

EHA 2019: Phase 3 randomised study of daratumumab plus D-VTd vs VTd in transplant-eligible newly diagnosed multiple myeloma

(14 Jun 2019)

EHA 2019: Genomic evidence of residual disease in patients in remission prior to stem cell transplant; fate or opportunity for early intervention?

(14 Jun 2019)

EHA 2019: Imetelstat in lower risk myelodysplastic syndromes refractory to erythropoietic stimulating agents

(14 Jun 2019)

EHA 2019: Labor is the most frequent outcome in the European Leukemia Net registry of patients with chronic myeloid leukaemia and pregnancy

(14 Jun 2019)

EHA 2019: Introduction of a new fixed-duration targeted therapy with venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukaemia and coexisting comorbidities

(14 Jun 2019)

FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma

(11 Jun 2019)

View all articles from the past year >

follow us

Tobacco Dependence e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation